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Introduction:  Aminoglycosides  (AGs)  have  been  widely  used  for  potential  life-threatening  bacterial  infec-
tions. Although  AGs  are  well  known  for their  ototoxic  side  effects,  some  AGs  such  as  amikacin  are
considered  less  harmful  to auditory  functions;  thus,  auditory  monitoring  is mostly  neglected  during
treatment  with  these  drugs.
Objective:  To  reﬂect  the  potential  auditory  hazards  of  repeated  amikacin  use  on  the  patients  with  cystic
ﬁbrosis  (CF).
Method: 32CF  patients  with  prior  exposure  to at least  3 courses  of amikacin  (the  CF  group)  and  35 non-
CF  patients  visiting  the  outpatient  clinic  with  any  complaint  other  than  hearing  loss  and  no  history  of
treatment  with  any  AG(the  control,  or  C  group)  were  compared  with  pure-tone  audiometry(PTA).  The
diagnosis  of CF was  made  by  Nanoduck  sweat  test.
Results:  The  average  age  of the  participants  were  8.25 ± 2.76 years  in  the  CF group  and  8.58 ± 2.00 years  in
the  C  group  (ranging  from  5  to 13 years).  29 (43.28%)  of  the  cases  were  female  and  38 (56.71%)  were  male.
Clinical  SNHL(sensorineural  hearing  loss)  was detected  in 4 of the  32  subjects  in the  CF group.  None  of the
subjects  in the  C group  exhibited  clinical  SNHL.  There  was  no  statistically  signiﬁcant  difference  between
the  groups  with  regard  to presence  or absence  of  clinical  SNHL  (p > 0.05).  However,  hearing  levels  of  the
CF group  were  around  20 dB(decibel)  HL(hearing  loss),  whereas  hearing  levels  of the  C  group  were  around
5  dB. This  difference  was  statistically  signiﬁcant  for  the pure  tone  averages  of both  all  frequencies  and
speech  frequencies  (p  <  0.05).
Conclusion:  Repetitive  exposure  to AGs  can  cause  permanent,  although  mild,  sensorineural  hearing  loss.
For  prevention,  hearing  status  of  the  patient  should  be closely  monitored  and  treatment  of choice  should
be  precisely  tailored  according  to  the audiological  evaluation.  This  is  especially  important  in  patients
with CF  who  frequently  experience  medical  conditions  necessitating  AGs  use.
©  2016  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Aminoglycosides (AGs) are bactericidal antibiotics which have
een widely used for potentially life-threatening bacterial infec-
ions since their invention in 1944 [1]. They are especially
mportant in certain medical conditions such as cystic ﬁbrosis (CF),
ainly due to the high bactericidal activity against Pseudomonas
eruginosa, the ability to reach high concentrations in respiratory
ecretions, and the synergistic effect with beta-lactam antibiotics
∗ Corresponding author at: Bursa Training and Research Hospital, Department of
torhinolaryngology, 16800 Yıldırım, Bursa, Turkey.
E-mail addresses: solmazfevzi@hotmail.com, drfsolmaz@gmail.com (F. Solmaz).
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214-7500/© 2016 Published by Elsevier Ireland Ltd. This is an open access article under tlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
[2,3]. They are also readily available worldwide, since they are
cost-effective and easy to produce in large amounts. These advan-
tages, however, are limited by the ototoxicity of this class of drugs,
which is aggravated by their repeated use in these patients. Clin-
ical studies report a rate of sensorineural hearing loss through a
range of 0–17% in CF patients [4,5]. Newer AGs such as amikacin and
netilmicin are considered less harmful to auditory functions; thus,
in most instances auditory monitoring is neglected by physicians
responsible for treating these patients. This study presents audi-
tory evaluation of pediatric CF patients who  had been repeatedly
treated with amikacin and compares it to that of healthy children
of the same age group.
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Comparison of the hearing results between groups.
Variables L(left),
R(right)
CF(Cystic
Fibrosis)
C(Control) P value
Audiometry mean(500, 1000,
2000,4000Hz > 25 dB)
L 4/32 0/35 >0.05
R  4/32 0/35 >0.05
Audiometry mean(500, 1000, 2000,
4000Hz > 15 dB)
L 21/32 0/35 <0.05
R  30/32 0/35 <0.05
Table 2
Comparison of the mean hearing levels.
Variables L(left),
R(right)
CF(Cystic Fibrosis)
(Mean ± SD)
C(Control)
(Mean ± SD)
P value
Audiometric mean of all frequencies L (dB) 17.96 ± 5.27 5.86 ± 2.58 0.00004
R(dB) 21.39 ± 4.20 5.43 ± 2.78 0.01018
Audiometric mean of 500, 1000, 2000,
4000 Hz frequencies
L(dB) 16.25 ± 4.91 5.32 ± 2.71 0.00048
R(dB) 20.52 ± 4.52 5.15 ± 2.80 0.00366
Table 3
The Mean ± SD of 250, 500, 1000, 2000, 4000 and 8000 Hz frequencies in the CF group.
Case 250 Hz 500 Hz 1000 Hz 2000 Hz 4000 Hz 8000 Hz
Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB)
1 18 22 18 21 15 22 17 24 28 25 30 25
2  20 27 21 24 10 36 16 30 22 32 25 33
3  14 25 10 25 17 22 16 21 18 20 20 23
4  13 25 10 25 15 16 15 17 15 21 21 20
5  22 20 22 24 20 16 16 13 21 22 24 22
6  20 21 27 20 21 23 23 21 29 25 31 24
7  21 20 20 19 14 17 13 18 15 22 16 23
8  16 18 15 15 15 18 11 17 17 21 20 22
9  17 19 15 23 13 17 15 20 16 26 20 24
10  16 14 14 23 16 12 15 15 20 17 22 20
11  22 13 19 25 13 13 11 12 24 16 27 18
12  10 22 10 23 12 18 10 19 16 22 18 21
13  30 19 30 18 27 17 25 19 27 21 29 21
14  15 23 14 25 12 16 12 20 15 22 18 24
15  21 25 21 24 20 15 23 15 22 19 22 23
16  26 25 25 26 26 25 25 25 26 25 30 26
17  15 20 14 15 15 15 18 25 17 18 20 20
18  13 20 11 15 15 15 16 22 20 18 23 20
19  18 21 14 22 15 15 22 20 21 18 25 20
20  15 22 12 24 13 15 16 17 17 18 20 20
21  12 19 11 19 23 16 15 18 17 18 20 19
22  11 20 10 18 13 25 15 21 22 18 23 18
23  12 21 12 21 13 20 13 22 17 18 19 19
24  14 21 15 20 12 21 16 22 16 28 18 25
25  17 19 16 17 14 17 18 18 18 20 22 22
26  17 18 12 18 15 16 13 18 14 22 17 24
27  12 18 10 15 14 17 13 16 15 25 17 23
28  19 20 19 21 20 19 18 18 20 22 20 23
29  21 20 20 18 23 19 21 18 22 20 22 21
30  27 26 25 25 25 25 25 25 26 26 32 27
7 ± 5.8
2
2
t
g
C
h
a
b
g
h
h31  26 26 25 24 25 24 
32  20 23 19 22 17 18 
Mean  ± SD17.00 ± 4.8121.56 ± 3.3416.18 ± 5.7721.50 ± 3.5416.06 ± 4.68 19.8
. Material and methods
.1. Groups
The study design was approved by the ethics committee of
he study center. This study was designed prospectively with two
roups. A total of 67 subjects were enrolled. The ﬁrst group (the
F group, or cystic ﬁbrosis) was composed of 32CF patients who
ad history of at least three courses of intravenous treatment with
mikacin 10–30 mg/kg daily for at least 10 days per episode, mostly
ecause of pulmonary infections but not for meningitis. The second
roup (the control group, or C group) consisted of 35 children who
ad visited the pediatric outpatient clinic for any reason other than
earing loss and had no history of exposure to any AGs.25 25 26 26 26 26
18 16 19 19 21 21
616.50 ± 4.5020.18 ± 3.9719.62 ± 4.4422.25 ± 4.1022.43 ± 4.76 23.00 ± 3.66
2.2. Diagnosis of CF
For the diagnosis of CF, Nanoduck sweat test was performed
three times to every patient in the CF group. The test was accepted
as positive, suspicious and negative when the result was  over
80 mmol/l, between 60 and 80 mmol/l and under 60 mmol/l respec-
tively. Sweat test results ranged between 50 and 122 mmol/l. An
informed consent was  taken from the patient’s parents and a pro-
tocol was  ﬁlled.2.3. Auditory evaluation
All subjects were examined otoscopically (HEINE® K-100 Diag-
nostic Otoscope, HEINE Optotechnic, Herrsching, Germany) to
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Table  4
The Mean ± SD of 250, 500, 1000, 2000, 4000 and 8000 Hz frequencies in the C group.
Case 250 Hz 500 Hz 1000 Hz 2000 Hz 4000 Hz 8000 Hz
Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB) Left (dB) Right(dB)
1 2 3 3 0 3 3 2 3 4 5 6 8
2  2 5 4 2 3 3 5 5 5 5 7 7
3  0 2 5 0 5 2 6 2 4 4 5 5
4  4 5 5 4 5 5 7 6 4 5 5 6
5  0 3 0 3 5 3 4 4 5 5 5 5
6  0 0 3 0 3 0 6 5 5 5 7 5
7  5 4 4 4 5 5 5 5 6 5 8 9
8  4 0 0 0 0 3 0 0 3 3 5 3
9  4 8 5 8 3 10 5 9 10 11 9 12
10  12 13 9 10 10 11 9 11 9 11 11 13
11  8 9 5 8 6 8 5 6 5 8 5 8
12  8 2 5 2 5 6 5 4 7 3 7 4
13  7 3 5 2 5 4 3 3 6 5 7 5
14  6 6 6 5 4 5 5 5 5 5 5 6
15  5 4 4 6 6 5 5 6 7 8 7 9
16  11 10 10 9 10 8 11 9 11 10 14 10
17  6 5 5 5 6 5 5 7 7 6 10 7
18  8 4 8 4 6 3 9 5 9 5 9 5
19  5 5 5 4 5 3 6 3 5 5 8 7
20  4 5 0 5 4 5 0 5 7 5 8 6
21  0 0 0 0 0 2 0 3 0 5 4 6
22  5 5 3 5 6 4 5 4 7 5 9 8
23  6 5 5 6 5 7 5 7 6 5 5 6
24  5 0 5 0 6 5 4 6 5 6 8 6
25  0 0 0 0 5 4 5 3 8 6 7 6
26  8 3 6 3 5 3 6 5 9 6 11 9
27  10 9 8 7 8 8 6 4 5 4 9 8
28  10 8 8 7 5 8 5 6 5 7 9 3
29  4 5 4 5 5 6 5 7 8 6 10 10
30  5 7 5 8 5 6 5 6 5 5 8 11
31  4 6 4 5 5 8 6 8 7 7 8 8
32  8 7 6 6 8 6 8 8 11 8 14 10
33  5 3 0 0 0 0 4 5 2 3 5 4
34  8 3 6 5 6 4 10 5 10 6 12 9
6 ± 2.5
p
p
s
a
8
a
a
2
a
4
2
m
n
n
A
A
2
I
S
a35  6 9 5 9 5 8 
Mean  ± SD 7.00 ± 2.97 5.00 ± 3.74 5.46 ± 3.01 4.66 ± 3.55 5.26 ± 2.60 5.0
rove an intact tympanic membrane. All subjects were evaluated by
ure-tone audiometry (PTA). PTA tests were performed in standard
oundproof cabins. Air-bone conduction thresholds were assessed
t frequencies of 250 Hz, 500 Hz, 1000 Hz, 2000 Hz, 4000 Hz, and
000 Hz.
The pure-tone average hearing levels were calculated both at
ll frequencies (averages of the full frequency range between 250
nd 8000 Hz) and speech frequencies (averages of 500, 1000 and
000 Hz). Clinical sensorineural hearing loss (SNHL) was  deﬁned
s pure-tone average of the hearing levels at 500, 1000, 2000 and
000 Hz over 25 dB HL.
.4. Exclusion criteria
Exclusion criteria for both groups were the history of chronic
iddle ear disease, prior ear surgery, birth trauma, familial deaf-
ess, diseases causing hearing loss such as meningitis, history of
oise exposure and concurrent use of other known ototoxic agents.
dditional exclusion criteria for the C group were exposure to any
G antibiotic and any diagnosis or suspicion of CF.
.5. Data evaluationAll data were evaluated by using SPSS® version 11.0.1 (SPSS
nc. Chicago, IL, USA). Student’s t-test, Fisher’s Exact test and Chi-
quare Test were used for statistical analysis. p < 0.05 was accepted
s signiﬁcant.8 7 8 9 11 11
6 5.93 ± 3.10 5.58 ± 2.31 6.87 ± 2.60 5.88 ± 2.11 8.76 ± 2.84 7.11 ± 2.86
3. Results
In this study, a total of 67 cases was evaluated in two  groups: the
CF (Cystic Fibrosis) group (n:32) and the C (Control) group (n:35).
The average age of the participants were 8.25 ± 2.76 years in the
CF group and 8.58 ± 2.00 years in the C group (Ranging from 5 to
13 years). 29 (43.28%) of the cases were female and 38 (56.71%)
were male. Demographic distribution of the two  groups showed
no statistical signiﬁcance (p > 0.05).
For the CF group, all of the 32 subjects were evaluated with PTA.
Clinical SNHL was detected in 4 of them on both ears; of these 4
patients, 2 had been exposed to more than 8 courses of amikacin,
and the other 2 patients had received 7 and 5 courses respectively.
Of the control group, PTA was  performed in all of the 35 subjects.
None of the subjects in the C group exhibited clinical SNHL for
neither ear.
There was no statistically signiﬁcant difference between the
groups at the frequencies of 500, 1000, 2000 Hz with regard to
presence or absence of clinical SNHL (p > 0.05) (Table 1). Pure-tone
averages were higher than 15 dB in 30 right and 21 left ears of 32
patients in the CF group, whereas none of the ears in the C group
of patients exhibited this phenomenon (p < 0.05) (Table 1).
During statistical analysis of hearing levels of the normal ears
with PTA, we  realized that mean pure-tone average hearing levels
of the CF group were around 20 dB, whereas that of the C group
were around 5 dB. This difference was  statistically signiﬁcant for
the pure tone averages of both all frequencies (250– 8000 Hz) and
speech frequencies (500–2000 Hz) (p < 0.05) (Table 2).
4 gy Re
i
T
4
l
a
w
e
o
w
r
d
o
(
A
i
[
t
s
A
w
[
c
l
w
t
w
a
h
d
y
c
b
i
w
t
t
g
T
m
H
i
r
w
s
b
g
o
5
p
t
[
[
[
[
[
[
[
hearing screening in children with cystic ﬁbrosis on aminoglycosides: a
systematic review, Laryngoscope (July) (2015), http://dx.doi.org/10.1002/lary.
25409 (Epub ahead of print).
[19] O.W. Guthrie, Aminoglycoside induced ototoxicity, Toxicology 249 (2–3)
(2008) 91–96.04 F. Solmaz et al. / Toxicolo
Audiometric mean of all frequencies and speech frequencies
n patients with CF and participants of C group were shown in
ables 3 and 4.
. Discussion
CF patients are repetitively exposed to AGs throughout their
ives due to frequent exacerbations of pulmonary infections which
re mainly pseudomonal. Moreover, doses of the antibiotics, even
hen they are given in combination, should be high in order to be
fﬁcacious in these patients [6]. These factors increase the risk of
totoxicity seen with this class of antibiotics.
Although AGs are frequently used drugs, there are few studies
hich detected hearing loss in these patients. Rates of sensorineu-
al hearing loss were reported in a range between 0% and 62%
epending on the AG used, the number of courses given, the amount
f cumulative dose, and the method used to detect hearing loss
i.e. PTA vs DPOAE-Distorsion Product Otoacoustic Emission vs
BR-Auditory Brainstem Response) [5,16]. Whereas former stud-
es conducted with PTA had detected SNHL rates of up to 6%
4,5,9], more recent studies conducted with newer, more sensitive
echniques such as high frequency PTA, DPOAE and ABR demon-
trated higher prevalences, especially if patients had been given
Gs repeatedly [14,15].
Studies demonstrate that AG ototoxicity is directly correlated
ith the number of treatment courses, hence the cumulative dose
10,13,17]. One recent systematic review including twelve studies
onducted between 1979 and 2014 reported an overall SNHL preva-
ence of 0–29% in CF children treated with aminoglycosides; this
as increased to 44% if the number of treatment courses was more
han 10 [18]. Also in our study 2 of the 4 patients in the CF group
ith SNHL had been exposed to more than 8 courses of amikacin.
The type of hearing loss due to AG treatment is mostly seen
t high frequencies [19], so a high frequency PTA may  demonstrate
earing loss at an earlier stage. Also some studies suggest an earlier
etection of cochlear damage with DPOAE, which is also useful in
oung children unsuitable for PTA [7,10]. We  were able to perform
onventional PTA (250–8000 Hz) to every patient.
An important consideration in the evaluation of these patients
y means of hearing thresholds is what should be accepted as “hear-
ng loss”. If 25 dB HL was accepted as SNHL, none of our patients
ould have SNHL; so, the rate of hearing loss in our amikacin-
reated CF patients would be 0%. However, hearing thresholds of
hese patients were signiﬁcantly higher than that of the control
roup consisting of healthy children with no exposure to any AG.
hus, it can be safe to say that at least 3 courses of amikacin treat-
ent causes a subclinical sensorineural hearing loss in CF patients.
owever, hearing loss may  be a result of many variables, even CF
tself may  be a factor. Especially in a setting that does not include a
eal control group (which should, in our study, consist of CF patients
ith no exposure to any AG), this cannot be predicted clearly. But
ince it would be very difﬁcult to comprise such a control group
ecause it is hard to encounter such patients in real life, our control
roup consisted of healthy children. This is a major limitation of
ur study.
. ConclusionRepetitive exposure to aminoglycoside antibiotics can cause
ermanent, although mild, sensorineural hearing loss. For preven-
ion, hearing status of the patient should be closely monitored andports 3 (2016) 401–404
treatment of choice should be precisely tailored according to the
audiological evaluation. This is especially important in patients
with cystic ﬁbrosis who  frequently experience medical conditions
necessitating the use of aminoglycosides.
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